Skip to main content
. 2022 Aug 26;149(7):3895–3903. doi: 10.1007/s00432-022-04297-3

Table 2.

Responses to EGFR-TKIs monotherapy and co-administration of EGFR-TKIs with SFI targeted-therapy schedule according to RECIST (n = 88)

Best overall response Number of cases (%)
Complete response 0 (0.0%)
Partial response 48 (54.5%)
Stable disease 40 (45.5%)
Progressive disease 0 (0.0%)